Venus Remedies Limited has informed the Exchange regarding Outcome of Board Meeting held on May 26, 2026.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.1 pts more than Nifty Microcap 250 and 5.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Venus Remedies Limited reported strong FY2026 results with standalone revenue from operations of Rs. 768.73 crore, up 19.3% from Rs. 644.47 crore in FY2025. Standalone PAT surged 89% to Rs. 99.31 crore from Rs. 52.55 crore, while consolidated PAT grew 127% to Rs. 102.78 crore from Rs. 45.31 crore. EBITDA margin expanded significantly from ~14.1% to ~20.2% year-on-year. The Board recommended a final dividend of Rs. 10 per share (100% on Rs. 10 face value), payable after shareholder approval at the 37th AGM on August 20, 2026 (record date August 7, 2026). Key director appointments include Mr. Saransh Chaudhary (related to promoter Mr. Pawan Chaudhary who holds 15,68,000 shares) as Independent Director and Dr. Savita Guta as Additional Director. The company also adopted new MOA and AOA to align with the Companies Act, 2013. Statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated results.
Strong operational performance with near-doubling of PAT and margin expansion signals underlying business strength. The large related-party director appointment (Saransh Chaudhary, son of controlling shareholder Pawan Chaudhary) warrants shareholder attention. Clean audit opinions with no going concern issues support financial health.